News for BridgeBio Pharma Inc Stock (BBIO)

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

Benzinga • Tuesday

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

GlobeNewsWire • Monday

BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director

Business Wire • Monday

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

GlobeNewsWire • Monday

BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats

Seeking Alpha • 11/14/24

BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates

Zacks Investment Research • 11/12/24

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management

GlobeNewsWire • 11/05/24

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks Investment Research • 10/31/24

BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors

Business Wire • 10/30/24

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

GlobeNewsWire • 10/24/24

3 Top Stocks That Could Still Rocket Higher in 2024

The Motley Fool • 10/04/24

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

GlobeNewsWire • 10/03/24

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

Benzinga • 09/30/24

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

GlobeNewsWire • 09/30/24

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

GlobeNewsWire • 09/27/24

3 Best High-Growth Mid-Cap Stocks to Buy in September 2024

24/7 Wall Street • 09/18/24

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

GlobeNewsWire • 09/17/24

BridgeBio to stop development of therapy for genetic disorder

Reuters • 09/10/24

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

GlobeNewsWire • 09/10/24

BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program

GlobeNewsWire • 09/10/24

BridgeBio Oncology Therapeutics (BBOT) Announces the Appointment of Yong Ben, MD, as Chief Medical and Development Officer

Business Wire • 09/09/24

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire • 09/06/24

BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis

Seeking Alpha • 08/31/24

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

GlobeNewsWire • 08/30/24

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

GlobeNewsWire • 08/29/24